CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: RNF216 (ImmuneEditome ID:54476)

1. Gene summary of enriched editing regions for RNF216

check button Gene summary
Gene informationGene symbol

RNF216

Gene ID

54476

GeneSynonymsCAHH|TRIAD3|U7I1|UBCE7IP1|ZIN
GeneCytomap

7p22.1

GeneTypeprotein-coding
GeneDescriptionE3 ubiquitin-protein ligase RNF216|RING-type E3 ubiquitin transferase RNF216|triad domain-containing protein 3|ubiquitin-conjugating enzyme 7-interacting protein 1|zinc finger protein inhibiting NF-kappa-B
GeneModificationdate20230517
UniprotIDQ9NWF9;F8W6D1;F8WDI8;C9JIV3
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr7:5644554-5645843:-ENST00000469375.1ENSG00000011275.17RNF216ncRNA_intronicAluSz,AluSx4,L1MB5,AluSx1chr7:5644554-5645843:-.alignment
chr7:5644554-5645843:-ENST00000484458.2ENSG00000011275.17RNF216ncRNA_intronicAluSz,AluSx4,L1MB5,AluSx1chr7:5644554-5645843:-.alignment
chr7:5649103-5649496:-ENST00000469375.1ENSG00000011275.17RNF216ncRNA_intronicAluJb,AluSx1chr7:5649103-5649496:-.alignment
chr7:5649103-5649496:-ENST00000484458.2ENSG00000011275.17RNF216ncRNA_intronicAluJb,AluSx1chr7:5649103-5649496:-.alignment
chr7:5660421-5661730:-ENST00000484458.2ENSG00000011275.17RNF216ncRNA_intronicAluSz,AluJb,FRAM,AluSc,AluSz6,MIRbchr7:5660421-5661730:-.alignment
chr7:5682444-5682674:-ENST00000484458.2ENSG00000011275.17RNF216ncRNA_intronicAluSx1chr7:5682444-5682674:-.alignment
chr7:5739830-5740426:-ENST00000389900.7ENSG00000011275.17RNF216intronicAluSx,AluYchr7:5739830-5740426:-.alignment
chr7:5739830-5740426:-ENST00000389902.6ENSG00000011275.17RNF216intronicAluSx,AluYchr7:5739830-5740426:-.alignment
chr7:5739830-5740426:-ENST00000425013.5ENSG00000011275.17RNF216intronicAluSx,AluYchr7:5739830-5740426:-.alignment
chr7:5742684-5743180:-ENST00000389900.7ENSG00000011275.17RNF216intronicAluSc5,L1ME3G,AluSxchr7:5742684-5743180:-.alignment
chr7:5742684-5743180:-ENST00000389902.6ENSG00000011275.17RNF216intronicAluSc5,L1ME3G,AluSxchr7:5742684-5743180:-.alignment
chr7:5742684-5743180:-ENST00000411812.1ENSG00000011275.17RNF216intronicAluSc5,L1ME3G,AluSxchr7:5742684-5743180:-.alignment
chr7:5742684-5743180:-ENST00000425013.5ENSG00000011275.17RNF216intronicAluSc5,L1ME3G,AluSxchr7:5742684-5743180:-.alignment


Top

2. Tumor-specific enriched editing regions for RNF216


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
ENSG00000011275.17,RNF216BRCAEAG1.2817e-04image
ENSG00000011275.17,RNF216PRADEAG8.1287e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr7:5660421-5661730:-STADEER4.1897e-024.1025e-021.8475e+02image

Top

3. Enriched editing regions and immune related genes for RNF216


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for RNF216


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000011275.17,RNF216
PCPGEAGA3ENSG00000029363.11chr6136279762:136279866:136277864:136278770:136277864:1362787760.29042.1058e-022.4772e-060.4132imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;RBM5;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YTHDF1;YWHAG;ZNF184BCLAF1MonocytesGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS
ENSG00000011275.17,RNF216
PCPGEAGIRENSG00000215193.8chr2218077922:18078047:18078295:18078606-0.29601.6460e-027.8353e-06-0.4001imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;RBM5;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;YWHAG;ZNF184NAGSVA_HALLMARK_HEDGEHOG_SIGNALING
ENSG00000011275.17,RNF216
PCPGEAGA3ENSG00000148396.14chr9136446854:136447006:136445051:136445111:136445051:1364457190.38391.9200e-037.0028e-090.4713imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MBNL1;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;RBM5;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YTHDF1;YWHAG;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000011275.17,RNF216
PCPGEAGIRENSG00000149926.9chr1630024426:30025467:30025725:300257690.33802.2708e-027.6537e-070.4063imageNADAR;CSTF2T;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;ELAVL3;FBL;FUS;GTF2F1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;IGF2BP2;IGF2BP3;NOP56;NOP58;NUMA1;PTBP1;RANGAP1;RBFOX2;RBM10;RBM5;SLTM;SND1;SRSF1;TAF15;TARDBP;U2AF2;UPF1;YTHDC1;ZNF184NAGSVA_HALLMARK_GLYCOLYSIS
ENSG00000011275.17,RNF216
PCPGEAGESENSG00000148396.14chr9136443822:136443900:136445644:136445719:136446854:136446949-0.53391.3062e-072.9546e-11-0.5292imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MBNL1;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;RBM5;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_CD8GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000011275.17,RNF216
PCPGEAGA5ENSG00000105429.8chr1942359097:42359242:42358143:42358307:42358143:42358954-0.36315.6119e-049.8406e-07-0.4311imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YTHDF1;YWHAG;ZNF184NAEosinophilsGSVA_HALLMARK_HYPOXIA
ENSG00000011275.17,RNF216
PCPGEAGESENSG00000105429.8chr1942370700:42370831:42371349:42371482:42375506:42375773-0.43435.0478e-054.9982e-07-0.4152imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YTHDF1;YWHAG;ZNF184NAB_cells_memoryGSVA_HALLMARK_HYPOXIA
ENSG00000011275.17,RNF216
PCPGEAGA5ENSG00000166295.4chr1072223887:72224056:72216047:72216138:72216047:72220379-0.41865.9028e-045.0741e-08-0.4436imageNADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YWHAG;ZNF184NAPlasma_cellsGSVA_HALLMARK_HYPOXIA
ENSG00000011275.17,RNF216
PCPGEAGA5ENSG00000123159.11chr1914482856:14483006:14491655:14491743:14484001:14491743-0.39253.3018e-058.4260e-09-0.4675imageNADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YTHDF1;ZNF184GIPC1Plasma_cellsGSVA_HALLMARK_TGF_BETA_SIGNALING
ENSG00000011275.17,RNF216
PCPGEAGA3ENSG00000148396.14chr9136446854:136446949:136443822:136443900:136443822:1364457190.50392.1400e-062.6139e-100.5069imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MBNL1;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;RBM5;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

More results



Top

5. Enriched editing regions and immune infiltration for RNF216


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000011275.17,RNF216BLCAEAGDendritic_cells_resting1.9658e-030.3105image
ENSG00000011275.17,RNF216BRCAEAGT_cells_CD4_naive5.4961e-040.1442image
ENSG00000011275.17,RNF216CESCEAGT_cells_CD4_memory_activated1.9335e-02-0.3475image
ENSG00000011275.17,RNF216COADEAGDendritic_cells_activated7.8975e-080.8402image
ENSG00000011275.17,RNF216ESCAEAGDendritic_cells_resting1.7782e-02-0.2402image
ENSG00000011275.17,RNF216GBMEAGMast_cells_activated2.7801e-02-0.2669image
ENSG00000011275.17,RNF216KIRCEAGEosinophils6.9590e-080.5170image
ENSG00000011275.17,RNF216KIRPEAGNK_cells_resting1.0212e-050.7501image
ENSG00000011275.17,RNF216LGGEAGT_cells_CD4_memory_activated3.1713e-060.2289image
ENSG00000011275.17,RNF216LUADEAGT_cells_CD4_memory_activated1.1227e-030.2310image
ENSG00000011275.17,RNF216LUSCEAGT_cells_CD4_memory_activated2.9556e-050.3154image
ENSG00000011275.17,RNF216OVEAGMast_cells_resting1.0730e-030.2466image
ENSG00000011275.17,RNF216PCPGEAGT_cells_regulatory_(Tregs)3.5718e-030.2464image
ENSG00000011275.17,RNF216PRADEAGT_cells_regulatory_(Tregs)1.8362e-030.2707image
ENSG00000011275.17,RNF216SKCMEAGT_cells_CD4_naive1.4434e-020.2306image
chr7:5739830-5740426:-STADEERMacrophages_M24.0892e-030.5169image
chr7:5742684-5743180:-STADEERNeutrophils3.3285e-030.4378image
ENSG00000011275.17,RNF216STADEAGNK_cells_resting1.9058e-02-0.1621image
ENSG00000011275.17,RNF216TGCTEAGT_cells_CD4_memory_activated5.0372e-030.4514image
ENSG00000011275.17,RNF216THCAEAGMacrophages_M13.5609e-02-0.1590image
ENSG00000011275.17,RNF216THYMEAGNK_cells_resting2.8415e-050.5811image


Top

6. Enriched editing regions and immune gene sets for RNF216


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000011275.17,RNF216STADEAG5.9334e-03-0.18972.2262e-02-0.15813.2779e-02-0.14771.5997e-02-0.1665image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000011275.17,RNF216BLCAGSVA_HALLMARK_ANDROGEN_RESPONSEEAG4.4714e-03-0.2863image
ENSG00000011275.17,RNF216BRCAGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG4.0496e-05-0.1709image
ENSG00000011275.17,RNF216CESCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG4.4026e-030.4168image
ENSG00000011275.17,RNF216COADGSVA_HALLMARK_HEME_METABOLISMEAG1.4388e-05-0.7419image
ENSG00000011275.17,RNF216ESCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.4848e-03-0.3183image
ENSG00000011275.17,RNF216GBMGSVA_HALLMARK_KRAS_SIGNALING_UPEAG5.8497e-03-0.3309image
ENSG00000011275.17,RNF216HNSCGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.6015e-03-0.3022image
ENSG00000011275.17,RNF216KIRCGSVA_HALLMARK_NOTCH_SIGNALINGEAG1.7592e-04-0.3738image
ENSG00000011275.17,RNF216KIRPGSVA_HALLMARK_P53_PATHWAYEAG4.8012e-03-0.5356image
ENSG00000011275.17,RNF216LGGGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.0523e-070.2543image
ENSG00000011275.17,RNF216LIHCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.8032e-020.3123image
ENSG00000011275.17,RNF216LUADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.6911e-02-0.1705image
ENSG00000011275.17,RNF216LUSCGSVA_HALLMARK_APICAL_JUNCTIONEAG1.7428e-03-0.2391image
ENSG00000011275.17,RNF216MESOGSVA_HALLMARK_UV_RESPONSE_UPEAG1.0404e-020.4607image
ENSG00000011275.17,RNF216OVGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG3.0803e-06-0.3462image
ENSG00000011275.17,RNF216PAADGSVA_HALLMARK_DNA_REPAIREAG8.1045e-030.3209image
ENSG00000011275.17,RNF216PCPGGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.3877e-03-0.2696image
ENSG00000011275.17,RNF216PRADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.5342e-05-0.3604image
ENSG00000011275.17,RNF216SARCGSVA_HALLMARK_APICAL_JUNCTIONEAG3.0130e-02-0.1948image
ENSG00000011275.17,RNF216SKCMGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG1.3465e-02-0.2329image
chr7:5660421-5661730:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.7320e-030.3449image
chr7:5739830-5740426:-STADGSVA_HALLMARK_MYOGENESISEER5.3459e-040.6031image
ENSG00000011275.17,RNF216STADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG2.4801e-04-0.2509image
chr7:5742684-5743180:-STADGSVA_HALLMARK_APICAL_SURFACEEER1.7172e-020.3617image
ENSG00000011275.17,RNF216TGCTGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG1.3279e-020.4035image
ENSG00000011275.17,RNF216THCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG9.2023e-06-0.3283image
ENSG00000011275.17,RNF216THYMGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG7.7010e-030.3922image
ENSG00000011275.17,RNF216UCECGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.6948e-03-0.4155image
ENSG00000011275.17,RNF216UCSGSVA_HALLMARK_HEME_METABOLISMEAG4.6217e-02-0.4022image


Top

7. Enriched editing regions and drugs for RNF216


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000011275.17,RNF216BRCAAxitinibEAG4.2227e-040.1472image
ENSG00000011275.17,RNF216CESCBX.795EAG9.6520e-040.4754image
ENSG00000011275.17,RNF216COADBMS.509744EAG3.4727e-060.7742image
chr7:5660421-5661730:-ESCAAICAREER4.0451e-03-0.5093image
ENSG00000011275.17,RNF216ESCACHIR.99021EAG7.1732e-040.3377image
ENSG00000011275.17,RNF216GBMBMS.754807EAG1.4881e-030.3779image
ENSG00000011275.17,RNF216HNSCElesclomolEAG1.2204e-030.3338image
ENSG00000011275.17,RNF216KIRCAS601245EAG1.5457e-040.3768image
ENSG00000011275.17,RNF216KIRPAS601245EAG3.3666e-030.5533image
ENSG00000011275.17,RNF216LGGBMS.708163EAG3.3219e-09-0.2882image
ENSG00000011275.17,RNF216LIHCCisplatinEAG3.2695e-02-0.2834image
ENSG00000011275.17,RNF216LUADBexaroteneEAG8.4418e-040.2365image
ENSG00000011275.17,RNF216LUSCEtoposideEAG1.6843e-03-0.2398image
ENSG00000011275.17,RNF216OVCHIR.99021EAG8.8117e-040.2506image
ENSG00000011275.17,RNF216PAADDMOGEAG2.9039e-020.2669image
ENSG00000011275.17,RNF216PCPGJNK.Inhibitor.VIIIEAG2.3407e-05-0.3517image
ENSG00000011275.17,RNF216PRADFH535EAG4.6648e-040.3026image
ENSG00000011275.17,RNF216SARCAKT.inhibitor.VIIIEAG3.7757e-05-0.3611image
ENSG00000011275.17,RNF216SKCMCyclopamineEAG1.4203e-03-0.2979image
chr7:5682444-5682674:-STADMG.132EER2.9575e-02-0.4641image
chr7:5660421-5661730:-STADABT.888EER2.2541e-03-0.3368image
chr7:5739830-5740426:-STADAZD.0530EER1.7376e-04-0.6514image
chr7:5644554-5645843:-STADCisplatinEER3.6702e-020.3965image
ENSG00000011275.17,RNF216STADAG.014699EAG1.6189e-03-0.2168image
ENSG00000011275.17,RNF216TGCTJNK.9LEAG1.5379e-03-0.5022image
ENSG00000011275.17,RNF216THCAEmbelinEAG1.2139e-100.4621image
ENSG00000011275.17,RNF216THYMAP.24534EAG5.4212e-040.4953image
ENSG00000011275.17,RNF216UCECFH535EAG1.9156e-030.4283image
ENSG00000011275.17,RNF216UCSAMG.706EAG4.1153e-02-0.4112image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType